Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label selgantolimod-containing combination therapies in chronic hepatitis B
2021-000672-11Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selgantolimod in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Primary endpoint: Functional cure at follow-up week 24. Started Oct 2021; status: completed.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-000672-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000672-11.